I Took A GLP-1 For Weight Loss — Here’s What Social Media Doesn’t Show You About The Experience
This is the reality TikTok won’t show you.View Entire Post ›
GLP-1 drugs linked to temporary hair loss: Here’s why
Thursday, July 30 – GLP-1 drugs linked to temporary hair loss: Here’s why
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
Thursday, July 30 – Shareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artificially inflated prices.”
Thyroid Meds Recalled Nationwide; Worst GLP-1 for Hair Loss? PMOS Prevalence
Wednesday, July 29 – (MedPage Today) — Major Pharmaceuticals issued a nationwide recall of multiple doses of levothyroxine sodium tablets, sold under the Major and Cardinal brands, due to subpotency. (USA Today)
The investigational triple agonist retatrutide met…
GLP-1 drugs may hold few benefits beyond physical health, study finds
Wednesday, July 29 – GLP-1 medications such as Ozempic have transformed the treatment of type 2 diabetes, helping millions of patients better control their blood sugar while reducing cardiovascular risk and, for many, promoting substantial weight loss.
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
Wednesday, July 29 – Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among others, in this space.
Trump’s Latest Name For GLP-1s Has Doctors And Patients Raising An Important Concern
Wednesday, July 29 – Despite the president’s comments, patients say these medications have been life-changing, and their effectiveness cannot be ignored.
Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism
Wednesday, July 29 – Altimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study.
Patients in the Phase 2 RECLAIM trial took a weekly shot of pemvidutide or placebo …
Can GLP-1s increase the risk of a rare eye condition?
Tuesday, July 28 – Can GLP-1s increase the risk of a rare eye condition?
Different GLP-1 therapies could be tailored to patients’ individual metabolic needs
Tuesday, July 28 – Different varieties and doses of GLP-1 medications can have meaningful differences in how they address heart and metabolic health issues, according to new research led by the Perelman School of Medicine at the University of Pennsylvania. Through an analysis of data from 19 randomized controlled trials, the researchers believe their work points to possible precision medicine applications of GLP-1s beyond weight loss. Their work is published in Diabetes, Obesity, and Metabolism.